These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1282452)
21. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Stevens MJ; Lattimer SA; Feldman EL; Helton ED; Millington DS; Sima AA; Greene DA Metabolism; 1996 Jul; 45(7):865-72. PubMed ID: 8692023 [TBL] [Abstract][Full Text] [Related]
22. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol. Tomlinson DR; Mayer JH Exp Neurol; 1985 Aug; 89(2):420-7. PubMed ID: 2410289 [TBL] [Abstract][Full Text] [Related]
23. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Kishi Y; Schmelzer JD; Yao JK; Zollman PJ; Nickander KK; Tritschler HJ; Low PA Diabetes; 1999 Oct; 48(10):2045-51. PubMed ID: 10512372 [TBL] [Abstract][Full Text] [Related]
24. Prevention of abnormalities in motor nerve conduction and nerve blood-flow by a prostacyclin analog, beraprost sodium, in streptozotocin-induced diabetic rats. Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima W Prostaglandins; 1995 Jun; 49(6):339-49. PubMed ID: 7480803 [TBL] [Abstract][Full Text] [Related]
25. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. Pop-Busui R; Sullivan KA; Van Huysen C; Bayer L; Cao X; Towns R; Stevens MJ Exp Neurol; 2001 Apr; 168(2):259-72. PubMed ID: 11259114 [TBL] [Abstract][Full Text] [Related]
26. Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve. Greene DA Drugs; 1986; 32 Suppl 2():6-14. PubMed ID: 3024950 [TBL] [Abstract][Full Text] [Related]
27. Altered sorbitol and myo-inositol metabolism as the basis for defective protein kinase C and (Na,K)-ATPase regulation in diabetic neuropathy. Greene DA; Lattimer SA Ann N Y Acad Sci; 1986; 488():334-40. PubMed ID: 3034118 [No Abstract] [Full Text] [Related]
28. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Greene DA; Mackway AM Diabetes; 1986 Oct; 35(10):1106-8. PubMed ID: 3019804 [TBL] [Abstract][Full Text] [Related]
29. Essential fatty acid treatment--effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats. Tomlinson DR; Robinson JP; Compton AM; Keen P Diabetologia; 1989 Sep; 32(9):655-9. PubMed ID: 2477293 [TBL] [Abstract][Full Text] [Related]
30. Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids. Head RJ; McLennan PL; Raederstorff D; Muggli R; Burnard SL; McMurchie EJ Am J Clin Nutr; 2000 Jan; 71(1 Suppl):386S-92S. PubMed ID: 10618002 [TBL] [Abstract][Full Text] [Related]
31. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na(+)-K(+)-ATPase activity, and vascular supply in STZ-D rats. Cameron NE; Cotter MA; Ferguson K; Robertson S; Radcliffe MA Diabetes; 1991 Dec; 40(12):1652-8. PubMed ID: 1661693 [TBL] [Abstract][Full Text] [Related]
32. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Hara T; Mori K; Nakashima E; Naruse K; Fukasawa H; Kakuta H; Sakamoto N Diabetes; 1996 Mar; 45(3):361-366. PubMed ID: 8593943 [TBL] [Abstract][Full Text] [Related]
33. Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine. Malone JI; Lowitt S; Corsico N; Orfalian Z Int J Clin Pharmacol Res; 1992; 12(5-6):237-41. PubMed ID: 1301404 [TBL] [Abstract][Full Text] [Related]
34. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition. Gillon KR; Hawthorne JN; Tomlinson DR Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913 [TBL] [Abstract][Full Text] [Related]
35. Effects of beraprost sodium, a prostacyclin analogue, on tail flick response in two models of diabetic-neuropathy in rats and its mechanism. Ueno Y; Koike H; Annoh S; Nishio S Life Sci; 1996; 59(9):PL105-10. PubMed ID: 8761032 [TBL] [Abstract][Full Text] [Related]
36. Relation of Na+, K(+)-ATPase to delayed motor nerve conduction velocity: effect of aldose reductase inhibitor, ADN-138, on Na+, K(+)-ATPase activity. Hirata Y; Okada K Metabolism; 1990 Jun; 39(6):563-7. PubMed ID: 2161992 [TBL] [Abstract][Full Text] [Related]
37. Vascular and metabolic factors in the pathogenesis of experimental diabetic neuropathy in mature rats. Wright RA; Nukada H Brain; 1994 Dec; 117 ( Pt 6)():1395-407. PubMed ID: 7820575 [TBL] [Abstract][Full Text] [Related]
38. Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat. Burnard SL; McMurchie EJ; Leifert WR; Patten GS; Muggli R; Raederstorff D; Head RJ J Diabetes Complications; 1998; 12(2):65-73. PubMed ID: 9559483 [TBL] [Abstract][Full Text] [Related]
39. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Cameron NE; Cotter MA; Hohman TC Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669 [TBL] [Abstract][Full Text] [Related]
40. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. Uehara K; Sugimoto K; Wada R; Yoshikawa T; Marukawa K; Yasuda Y; Kimura Y; Yagihashi S J Diabetes Complications; 1997; 11(3):194-202. PubMed ID: 9174902 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]